Chronic graft-versus-host disease (cGVHD) requires personalized, long-term management strategies that reflect the heterogeneity of organ involvement, disease severity, and patient priorities. A clear understanding of immune-mediated pathophysiology, evolving diagnostic criteria, and emerging targeted therapies is essential to guide treatment selection, thoughtful sequencing, and coordinated multidisciplinary care, thereby improving functional outcomes and quality of life for patients living with cGVHD.